查看文章

In the present study, we aimed to investigate the influence of clinical parameters and single-nucleotide polymorphisms of interleukin-6 receptor (rs12083537, rs2228145, rs4329505 and rs11265618) on response to tocilizumab, TCZ (European League Against Rheumatism (EULAR) response, remission, low disease activity (LDA) and improvement of DAS28). We performed a retrospective cohort study in patients with Rheumatoid Arthritis (RA) treated with TCZ for 12 months. Multivariable analysis showed that the only variable independently associated to satisfactory EULAR response (odds ratio (OR): 0.61; 95% of confidence interval (CI) 95%: 0.42, 0.88; P= 0.008), remission (OR: 0.51; CI 95%: 0.35, 0.75; P= 0.001), LDA (OR: 0.41; CI 95%: 0.24, 0.72; P= 0.002) and improvement in DAS28 (B=− 0.32; CI 95%):− 0.47,− 0.17; P= 7.5× 10− 5) at 12 months was lower number of previous biological therapy (BT). High …